State Street Corp Purchases 1,713,200 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

State Street Corp increased its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 864.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,911,327 shares of the biopharmaceutical company’s stock after purchasing an additional 1,713,200 shares during the quarter. State Street Corp owned approximately 3.53% of Emergent BioSolutions worth $15,960,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC boosted its holdings in shares of Emergent BioSolutions by 5.8% in the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 52,144 shares during the last quarter. American Century Companies Inc. raised its position in Emergent BioSolutions by 240.9% in the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after acquiring an additional 623,201 shares during the period. Assenagon Asset Management S.A. raised its position in Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after acquiring an additional 316,700 shares during the period. Marshall Wace LLP boosted its stake in Emergent BioSolutions by 75.4% in the second quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after acquiring an additional 233,341 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in shares of Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after acquiring an additional 253,960 shares during the period. 78.40% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on EBS shares. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark boosted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Emergent BioSolutions Stock Performance

NYSE EBS opened at $8.30 on Wednesday. The firm has a market cap of $449.73 million, a P/E ratio of -2.02 and a beta of 1.59. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company’s 50 day moving average is $9.28 and its 200-day moving average is $8.83. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.